BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220117
DTEND;VALUE=DATE:20220119
DTSTAMP:20260515T235328
CREATED:20210920T085620Z
LAST-MODIFIED:20211217T131548Z
UID:31698-1642377600-1642550399@www.pharmajournalist.com
SUMMARY:SMi’s 10th Annual Pharmaceutical Microbiology UK Conference
DESCRIPTION:SMi’s 10th Annual Pharmaceutical Microbiology UK Conference  \nConference: 17 – 18 January 2022\nWorkshops: 19 January 2022 \nLocation: Virtual Conference: Online Access Only  \nWebsite: http://www.pharma-microbiology.com/PJwl \nSponsored by: CTL-MAT\, Ecolab and Microgenetics \nChaired by: Di Morris\, Clinical Auditor\, AstraZeneca \nExploring Robust Risk-Based Microbiological Control Strategy \nSMi’s flagship microbiology conference is celebrating its 10 year anniversary. The conference taking place on 17 and 18 January 2021 in London\, UK will bring together microbiology industry experts. \nMicrobiology remains an essential tool for the detection of microorganisms present in biopharmaceutical and pharmaceutical batches. The two-day conference will explore the most pressing topics in this thriving field\, from the movement toward process automation and minimisation of operator intervention\, to the latest technologies in rapid microbiological testing methods and data integrity. \n#SMiPharmaMicroUK \nKey Reasons to Attend: \n\nDiscover case studies in establishing holistic Contamination Control Strategies and Real-Time Viable Air Particle Counting with leaders in the pharmaceutical industry\nGain insight the current state of Endotoxin testing\, including alternative test methods and strategic approaches to method validation\nExplore the best practice in data integrity and the automation of environmental monitoring in the Microbiology Quality Control Lab\nJoin the important panel discussion on diversity and inclusion in the workplace with an experienced line-up of speakers\nDiscuss the latest developments in the detailed\, rapid detection of microbes in pharmaceutical water\n\nDownload the brochure at: http://www.pharma-microbiology.com/PJwl \nWho Should Attend? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-10th-annual-pharmaceutical-microbiology-uk-conference/
LOCATION:London\, UK
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220118
DTEND;VALUE=DATE:20220121
DTSTAMP:20260515T235328
CREATED:20210928T103251Z
LAST-MODIFIED:20210928T103251Z
UID:31764-1642464000-1642723199@www.pharmajournalist.com
SUMMARY:3rd Glioblastoma Drug Development Summit
DESCRIPTION:The 3rd Glioblastoma Drug Development Summit is the only industry led forum for large pharma\, biotech and academic KOLs to unite under the common goal of accelerating the practical translation and clinical development of meaningful therapies for the treatment of glioblastoma. \nThrough investigating the clinical implementation of diverse mechanisms of action\, including\, DNA damage repair\, immunotherapy\, oncolytic viruses\, cholesterol metabolism\, PARP inhibitors and more\, we strive to address the urgent need for novel and much improved treatments for this devastating disease. \nTackling specific drug development challenges such as a better understanding of preclinical efficacy and tolerability data to confidently translate into the clinic\, improving drug delivery across the blood-brain barrier and optimizing clinical trial design to define more measurable outcomes\, this meeting is an absolute must attend for all neuro-oncologists and oncology professionals determined to translate their drug candidates into human clinical trials. \nWith a huge unmet medical need for effective treatments and too many clinical failures to overcome\, there has never been a more important time to attend the 3rd Glioblastoma Drug Development Summit and join your dedicated and determined community to defeat GBM and radically change patients’ lives. \nJoin us as we unite drug developers and academics to tackle unique drug development challenges creating obstacles for effective treatments for GBM patients. \nTo know more visit: https://ter.li/2bmg9q
URL:https://www.pharmajournalist.com/event/3rd-glioblastoma-drug-development-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR